Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @ActobioT
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ActobioT
-
Great news from our partners at
#Oragenics! Enrollment is now complete for their phase 2 clinical trial of AG013 for#oralmucositis. AG013 is an ActoBio Therapeutics Inc. candidate created on our#ActoBiotics® platform and licensed to Oragenics. More: http://actobio.com pic.twitter.com/PJ0V9inbEX
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you’re at
#BIOInvestorForum don’t miss#ActoBio Therapeutics™ CEO Pieter Rottiers presenting an overview of the innovative ActoBiotics® platform on Wednesday October 23 @ 9:15 AM. Read more: http://actobio.com or follow us on LinkedIn or Twitter@ActobioT#bif19#biotechpic.twitter.com/DE0Til8N2R
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you're at
#SynBioBeta, don't miss#ActoBio Therapeutics™ CEO Pieter Rottiers' presentation at 4PM today about the innovative ActoBiotics® platform. More: http://www.actobio.com or follow us on Twitter@ActobioT or LinkedIn.#actobiotics#healthcare#biotech#medicinepic.twitter.com/Kj0AsRsnzy
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you're attending
#SynBioBeta2019 don't miss#ActoBio Therapeutics™ CEO Pieter Rottiers' overview of the innovative#ActoBiotics® platform and its applications on October 1. Read more: http://actobio.com , follow us on Linkedin or Twitter@ActobioT#biotech#immunologypic.twitter.com/3RBSchnWqA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten. Read more: http://actobio.com/Home/News or follow us on LinkedIn or Twitter@actobioT#celiacdisease#immunotherapy#biotechpic.twitter.com/c8rGZRrxdP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
An interesting and thought-provoking article on the future of diabetes treatments from
@Labiotech_eu Read more about#ActoBiotics at http://actobio.com#type1diabetes#celltherapyhttps://twitter.com/Labiotech_eu/status/1150836177517326336 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of#type1diabetes. Read more: http://www.actobio.com/Home/News or follow us on LinkedIn or Twitter@actobioT#t1d#immunotherapy#biotechpic.twitter.com/dUaRGc1Sk4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Reminder: If you're at
#MicrobiomeSummit, don't miss#ActoBio Therapeutics™ CTO Lothar Steidler's presentation on Friday June 28. He will discuss the innovative ActoBiotics® platform and its applications. Read more: http://www.ActoBio.com#actobiotics#microbiome#biotechpic.twitter.com/SVc0GkAoYF
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Reminder:
#ActoBio Therapeutics™ CTO Lothar Steidler has been invited to present at the#MicrobiomeSummit on Friday June 28 in Boston. He will discuss the innovative ActoBiotics® platform and its applications. Read more: http://ActoBio.com#actobiotics#microbiome#biotechpic.twitter.com/WPBnPBOrxK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ActoBio Therapeutics™' CTO Lothar Steidler has been invited to talk about our innovative ActoBiotics® platform and its applications at#MicrobiomeSummit in Boston, on Friday June 28 at 3:50pm. Read more: http://ActoBio.com#actobiotics#microbiome#biotechpic.twitter.com/TuRQ93iGLa
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Reminder: Don't miss
#ActoBio Therapeutics™ CEO Pieter Rottiers' overview of the innovative#ActoBiotics® platform at#BIO2019 on Monday 3rd June, at 14:15. Read more: http://www.actobio.com or follow us on LinkedIn or Twitter@ActobioT#biotech#biopharmaceuticals#immunologypic.twitter.com/EBCAjeHx1c
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you are attending
#BIO2019, don't miss Pieter Rottiers' overview of the innovative ActoBiotics® platform on Monday 3rd June, at 14:15.https://twitter.com/Intrexon/status/1133392125062766592 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ActoBio Therapeutics™ CEO Pieter Rottiers will be presenting at
#BIO 2019 on Monday 3rd June, at 14:15. Read more: http://www.actobio.com or follow us on LinkedIn or Twitter@ActobioT.#actobiotics#immunotherapy#biotech#immunology#biopharmaceuticalspic.twitter.com/H5hPBsvflp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Reminder: ActoBio Therapeutics™ CEO Pieter Rottiers is at
#BioEquity Europe 2019 from 20 - 21 May 2019 in Barcelona. Read more: http://actobio.com , LinkedIn or Twitter@ActobioT.#actobiotics#immunotherapy#biotech#type1diabetes#celiacdiseasepic.twitter.com/1fiC54oADf
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ActoBio Therapeutics™ CEO Pieter Rottiers will be attending
#BioEquity Europe 2019 from 20 - 21 May 2019 in Barcelona. Read more: http://actobio.com , LinkedIn or Twitter@ActobioT.#actobiotics#immunotherapy#biotech#type1diabetes#celiacdiseasepic.twitter.com/ptkxRocAWR
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ActoBio Therapeutics™ are proud to announce that CTO Lothar Steidler has been elected VIB Alumni Awardee 2019. Read more: http://www.actobio.com/Home/News
@ActobioT@VIBLifeSciences#actobio#biotech#scicommpic.twitter.com/GNyFIK3OGR
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ActoBio Therapeutics™ proslijedio/la je Tweet
With the therapeutic potential of engineered cells, we may be closer than ever to curing diseases like type 1
#diabetes http://bit.ly/2FNPGGf@ActobioT@Intrexon#synbio#T1D#therapies#therapeutics#immunotherapy#type1diabetesHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Reminder: CEO Pieter Rottiers will participate in a panel discussion at 2nd Antigen-Specific Immune Tolerance Drug Development Summit in Boston on 28th March. Read more: http://ActoBio.com or LinkedIn.
#biotech#actobio#scicommpic.twitter.com/oML5fT7qdG
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ActoBio Therapeutics™ @ Antigen-Specific Immune Tolerance Drug Development Summit 2019: CEO Pieter Rottiers invited to take part in panel discussion in Boston on Thursday 28th March at 16:30. Read more: http://ActoBio.com or LinkedIn.
#biotech#actobio#scicommpic.twitter.com/cgJBcferPq
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Reminder: ActoBio Therapeutics™ CTO Lothar Steidler will talk about our innovative ActoBiotics® platform and its applications at Pharmabiotics 2019 in Paris, 13th – 14th March 2019. Read more: http://Actobio.com
#pharmabiotics#actobio#biotech#scicommpic.twitter.com/d6xeGL121Q
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.